News Archives

News Archives

Avivagen Announces Update on Private Placement Process

Ottawa, ON /Business Wire/ January 20, 2020 / — Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Company”), a life sciences innovation company with a series of patent protected products that support and optimize human and animal health, is pleased to provide an update on the status of its previously announced non-brokered private placement (the “Offering”) of …Read More

Avivagen Inc. Commences Trading on the OTCQB® Venture Market in the U.S.

Ottawa, ON / Business Wire / January 08, 2020 / – Avivagen Inc. (TSXV:VIV, OTCQB: VIVXF) (“Avivagen”), a life sciences innovation company with a series of patent protected products that support and optimize human and animal health, is pleased to announce that it has qualified to trade its common shares in the United States on …Read More

Avivagen Announces Closing of $1.25 Million Private Placement

Ottawa, ON /Business Wire/ January 3, 2020 / — Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Company”), a life sciences innovation company with a series of patent protected products that support and optimize human and animal health, is pleased to announce the successful completion of a non-brokered private placement (the “Offering”), issuing 2,500,000 units (the “Units”) …Read More

Avivagen Inc. Announces Results for Fiscal Year Ending October 31, 2019

Ottawa, ON /Business Wire/ December 19, 2019 / — Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Company”) today reported its audited financial results for the year ended October 31, 2019. Unless otherwise noted, all figures are in Canadian currency. The Company’s audited year end Financial Statements and its Management’s Discussion and Analysis for the year ended …Read More

Agreement with COFCO Biotechnology Sets Stage for Avivagen to Secure OxC-betaTM Livestock Approval in China

Ottawa, ON / Business Wire / December 17, 2019 / – Avivagen Inc. (TSXV:VIV) (“Avivagen”) has announced that it has entered into an agreement with the research subsidiary of COFCO Biotechnology  Co. Ltd.  (“COFCO”) pursuant to which COFCO will assist Avivagen with the approval process necessary to enter the Chinese market. With over 12,000 employees, …Read More

Avivagen Signs Memorandum of Understanding with Distribution Agent in Asia-Pacific

Deal with Manila-based INPHILCO intended to create new channel for OxC-betaTM Livestock with large integrated feed producers and commercial farms in the Philippines Ottawa, ON, December 16, 2019: – Avivagen Inc. (TSXV:VIV) (“Avivagen”) has entered into a memorandum of understanding with INPHILCO, Inc. setting out the terms under which the parties propose that INPHILCO will …Read More